FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

The designation was supported by results from the Phase III INBUILD® study that met its primary endpoint and was recently published in the New England Journal of Medicine RIDGEFIELD, Conn., Oct. 10, 2019 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, FDA Boehringer Ingelheim, Ofev, nintedanib, interstitial lung disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news